 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors
June 06, 2012
ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 14, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Enzo Launches Lung Cancer Dx; Zelboraf Survival Data; Caris' Tumor Profiling Service
November 14, 2012 / Pharmacogenomics Reporter - CHMP Recommends EU Approval of Roche PGx Drug Zelboraf
December 21, 2011 / Pharmacogenomics Reporter - FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter - Roche, BMS Hope to Improve Outcomes in BRAF-Mutated Melanoma Patients with Dual Treatment Regimen
June 8, 2011 / Pharmacogenomics Reporter